Stock 4508 MITSUBISHI TANABE PHARMA CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Press Releases Mitsubishi Tanabe Pharma Corporation

Equities

4508

JP3469000008

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Mitsubishi Tanabe Pharma : Canada Announces That Company's Treatment for Amyotrophic Lateral Sclerosis (ALS) Has Been Added to the Provincial Drug Plan in Quebec
AQ
Mitsubishi Tanabe Pharma : Canada Concludes Letter of Intent with Pan-Canadian Pharmaceutical Alliance for RADICAVA® (Edaravone)
AQ
Aytu BioScience : Announces Exclusive ZolpiMist License to Commercialize Aytu's Oral Spray Sleep Aid in South Korea
AQ
Mitsubishi Tanabe Pharma : Announcement of FY2019 3rd Quarter Financial Results ⇒R&D Pipeline "State of New Product Development"
PU
Mitsubishi Tanabe Pharma : Announcement of FY2019 2nd Quarter Financial Results ⇒R&D Pipeline "State of New Product Development"
PU
Mitsubishi Tanabe Pharma : Corporate Governance Corporate Governance Report
PU
Mitsubishi Tanabe Pharma : NMPA accepts our filing for TENELIA, a treatment agent for type 2 diabetes mellitus in China
PU
Mitsubishi Tanabe Pharma : Included in the Dow Jones Sustainability Asia Pacific Index
PU
Mitsubishi Tanabe Pharma : Monitoring indicators on “Materiality”
PU
Mitsubishi Tanabe Pharma : "Materiality" posted
PU
Mitsubishi Tanabe Pharma : Announcement of FY2018 2nd Quarter Financial Results ⇒R&D Pipeline "State of New Product Development"
PU
Mitsubishi Tanabe Pharma : Announcement of FY2018 1st Quarter Financial Results ⇒R&D Pipeline "State of New Product Development"
PU
Mitsubishi Tanabe Pharma : Corporate Governance Report
PU
Mitsubishi Tanabe Pharma : Notice of Resolution of the 11th Ordinary General Meeting of Shareholders
PU
Mitsubishi Tanabe Pharma : Notice of Convocation of the 11th Ordinary General Meeting of Shareholders
PU
Mitsubishi Tanabe Pharma : Announcement of Financial Results for FY2017 ⇒R&D Pipeline "State of New Product Development"
PU
Mitsubishi Tanabe Pharma : Announcement of FY2017 3rd Quarter Financial Results ⇒R&D Pipeline "State of New Product Development"
PU
Mitsubishi Tanabe Pharma : Launch of Rupafin tablets in Japan ―Allergy treatment agent with new mechanism of action shows strong effectiveness with dual action (anti-PAF and antihistamine action)
PU
Mitsubishi Tanabe Pharma : Announcement of FY2017 2nd Quarter Financial Results ⇒R&D Pipeline "State of New Product Development"
PU
Mitsubishi Tanabe Pharma : Completion of Transfer of Shares of Generic Drugs Subsidiary (Update of Previous Disclosure)
PU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 4508 Stock
  4. News Mitsubishi Tanabe Pharma Corporation
  5. Press Releases